Floatz logo

Durvalumab

Safety

The Affiliated Hospital of Qingdao Universitymonoclonal_antibodyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Safety cohort.

Asset / SponsorPhaseRating
Bortezomib
Shandong Provincial Hospital
Phase 4BB
Gemtuzumab Ozogamicin
Pfizer
Phase 4BB
Namenda
First Affiliated Hospital Xi'an Jiaotong University
Phase 4B
Famitinib
Anhui Provincial Hospital
Phase 3B
DEXAMETHASONE
Shandong Provincial Hospital
Phase 4B

View all 48 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →